These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27086168)

  • 1. A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo.
    Galvin O; Srivastava A; Carroll O; Kulkarni R; Dykes S; Vickers S; Dickinson K; Reynolds AL; Kilty C; Redmond G; Jones R; Cheetham S; Pandit A; Kennedy BN
    J Control Release; 2016 Jul; 233():198-207. PubMed ID: 27086168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis.
    Reynolds AL; Alvarez Y; Sasore T; Waghorne N; Butler CT; Kilty C; Smith AJ; McVicar C; Wong VH; Galvin O; Merrigan S; Osman J; Grebnev G; Sjölander A; Stitt AW; Kennedy BN
    J Biol Chem; 2016 Apr; 291(14):7242-55. PubMed ID: 26846851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and Development of the Quininib Series of Ocular Drugs.
    Mahon N; Slater K; O'Brien J; Alvarez Y; Reynolds A; Kennedy B
    J Ocul Pharmacol Ther; 2022; 38(1):33-42. PubMed ID: 35089801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
    Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
    J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.
    Murphy AG; Casey R; Maguire A; Tosetto M; Butler CT; Conroy E; Reynolds AL; Sheahan K; O'Donoghue D; Gallagher WM; Fennelly D; Kennedy BN; O'Sullivan J
    Sci Rep; 2016 Oct; 6():34523. PubMed ID: 27739445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosome-mediated delivery of an anti-angiogenic peptide inhibits pathological retinal angiogenesis.
    Dong X; Lei Y; Yu Z; Wang T; Liu Y; Han G; Zhang X; Li Y; Song Y; Xu H; Du M; Yin H; Wang X; Yan H
    Theranostics; 2021; 11(11):5107-5126. PubMed ID: 33859737
    [No Abstract]   [Full Text] [Related]  

  • 7. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
    Santulli RJ; Kinney WA; Ghosh S; Decorte BL; Liu L; Tuman RW; Zhou Z; Huebert N; Bursell SE; Clermont AC; Grant MB; Shaw LC; Mousa SA; Galemmo RA; Johnson DL; Maryanoff BE; Damiano BP
    J Pharmacol Exp Ther; 2008 Mar; 324(3):894-901. PubMed ID: 18083913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapy.
    Sulaiman RS; Merrigan S; Quigley J; Qi X; Lee B; Boulton ME; Kennedy B; Seo SY; Corson TW
    Sci Rep; 2016 May; 6():25509. PubMed ID: 27148944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis.
    Nakao S; Arima M; Ishikawa K; Kohno R; Kawahara S; Miyazaki M; Yoshida S; Enaida H; Hafezi-Moghadam A; Kono T; Ishibashi T
    Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4323-8. PubMed ID: 22661475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model.
    Ayalasomayajula SP; Kompella UB
    Eur J Pharmacol; 2005 Mar; 511(2-3):191-8. PubMed ID: 15792788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effects of bestatin in the retina of streptozotocin-induced diabetic mice.
    Hossain A; Heron D; Davenport I; Huckaba T; Graves R; Mandal T; Muniruzzaman S; Wang S; Bhattacharjee PS
    Exp Eye Res; 2016 Aug; 149():100-106. PubMed ID: 27344955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal thalidomide reduces experimental preretinal neovascularisation without induction of retinal toxicity.
    Vom Hagen F; Kamppeter BA; Erber R; Jonas JB; Hammes HP
    Br J Ophthalmol; 2010 Apr; 94(4):504-8. PubMed ID: 19713194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of diclofenac formulated in hyaluronan on angiogenesis in vitro and its intraocular tolerance in the rabbit eye.
    Shen WY; Constable IJ; Chelva E; Rakoczy PE
    Graefes Arch Clin Exp Ophthalmol; 2000 Mar; 238(3):273-82. PubMed ID: 10796042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein E2 and E3, but Not E4, Promote Retinal Pathologic Neovascularization.
    Masuda T; Shimazawa M; Hashimoto Y; Kojima A; Nakamura S; Suemori S; Mochizuki K; Kawakami H; Kawase K; Hara H
    Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):1208-1217. PubMed ID: 28241308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ antibody-loaded hydrogel for intravitreal delivery.
    Awwad S; Abubakre A; Angkawinitwong U; Khaw PT; Brocchini S
    Eur J Pharm Sci; 2019 Sep; 137():104993. PubMed ID: 31302214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits.
    Alikacem N; Yoshizawa T; Nelson KD; Wilson CA
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1561-9. PubMed ID: 10798677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity.
    Penn JS; Rajaratnam VS; Collier RJ; Clark AF
    Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):283-90. PubMed ID: 11133880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zebrafish (Danio rerio) embryo as a platform for the identification of novel angiogenesis inhibitors of retinal vascular diseases.
    Rezzola S; Paganini G; Semeraro F; Presta M; Tobia C
    Biochim Biophys Acta; 2016 Jul; 1862(7):1291-6. PubMed ID: 27085972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Flt1 peptide - hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy.
    Oh EJ; Choi JS; Kim H; Joo CK; Hahn SK
    Biomaterials; 2011 Apr; 32(11):3115-23. PubMed ID: 21277020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization.
    Kim J; Lima E Silva R; Shmueli RB; Mirando AC; Tzeng SY; Pandey NB; Ben-Akiva E; Popel AS; Campochiaro PA; Green JJ
    Acta Biomater; 2019 Oct; 97():451-460. PubMed ID: 31374338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.